On March 26, 2012, the U.S. Department of Health & Human Services Office of Inspector General (the “OIG”) published a report summarizing a February 23, 2012roundtable meeting between the OIG and compliance professionals from twenty-three pharmaceutical manufacturers. The compliance officers and other professionals attending the meeting all represented companies currently operating under Corporate Integrity Agreements (or “CIAs”). CIAs are generally negotiated between a company and the government in connection with settling various types of federal ...
Blog Editors
Recent Updates
- DOJ Civil Division Announces 2025 Priorities: Promises “Aggressive” False Claims Act Enforcement of Civil Rights Violations and “Impermissible” Gender-Affirming Care
- HealthBench: Exploring Its Implications and Future in Health Care
- Navigating the Legal Risks of Consumer Protection Claims in Healthcare
- Oregon SB 951, Regulating the Corporate Practice of Medicine, Is Signed into Law—But Changes May Be in the Works Already
- CMS Doubles Down on Medicare Advantage Recoupment: Announces Aggressive RADV Strategy to Reclaim Billions